Notice of Change in PAR-13-250 "NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44)"

Notice Number: NOT-AI-14-022

Key Dates
Release Date: January 15, 2014

Related Announcements
PAR-13-250

Issued by
National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

This Notice is to inform potential applicants that the NIAID is revising PAR-13-250, “NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44),” to clarify the exception of Fast-Track applications to the list of 'NOT supported' areas in the Commercialization Plan section of the FOA.

Part 2. Section I. Funding Opportunity Description

Commercialization Plan
Current Language
Awards made under the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44) FOA will NOT provide support for:

Modified Language
Awards made under the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44) FOA (except Fast-Track applications) will NOT provide support for:

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Natalia Kruchinin Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone:  301-496-8666
Email:  kruchininn@niaid.nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices



NIH Office of Extramural Research Logo
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®



Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.